Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

• Status: Recruiting
• Trial end date: 2028-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Nitazoxanide; Rifaximin

Criteria

Inclusion Criteria:

• Cirrhotic patient with at least one previous episode of hepatic encephalopathy.

• Adult Patients aging from 20 to 65 years old

Exclusion Criteria:

• Active GIT bleeding.

• Major psychiatric illness (psychosis & epilepsy).

• Renal insufficiency (S.Cr 2mg/dl).